FibroBiologics (STU:SG0) ROCE % : -155,600.00% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. FibroBiologics's annualized ROCE % for the quarter that ended in Mar. 2024 was -155,600.00%.

FibroBiologics ROCE % Historical Data

The historical data trend for FibroBiologics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics ROCE % Chart

FibroBiologics Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-10,122.97

FibroBiologics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial				-	-66.64	-71.01	-522.24	-155,600.00

FibroBiologics ROCE % Calculation

FibroBiologics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-14.982	/	( ( (4.554 - 6.677)	+	(10.84 - 8.421) )	/ 2 )
	=	-14.982	/	( (-2.123	+	2.419)	/ 2 )
	=	-14.982	/	0.148
	=	-10,122.97 %

FibroBiologics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-31.12	/	( ( (10.84 - 8.421)	+	(10.487 - 12.866) )	/ 2 )
	=	-31.12	/	( ( 2.419	+	-2.379 )	/ 2 )
	=	-31.12	/	0.02
	=	-155,600.00 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

FibroBiologics (STU:SG0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

FibroBiologics ROCE % Related Terms

Thank you for viewing the detailed overview of FibroBiologics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroBiologics (STU:SG0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (STU:SG0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

FBLG:USA

Address

455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598

Website

https://www.fibrobiologics.com

FibroBiologics Inc is an early-stage, cell therapy company. Its primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing, and other diseases.

FibroBiologics (STU:SG0) Headlines

No Headlines